The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | UK NCRI FLAIR trial: ibrutinib + venetoclax with MRD-directed duration of treatment in CLL
In this video, Talha Munir, MD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares findings from the Phase III UK NCRI FLAIR trial (ISRCTN01844152), which is comparing ibrutinib plus venetoclax (I+V) to fludarabine, cyclophosphamide and rituximab (FCR) in patients with previously untreated chronic lymphocytic leukemia (CLL). In this trial, I+V with measurable residual disease (MRD)-guided duration of treatment resulted in an improvement in both progression-free survival and overall survival (PFS; OS) in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
